AFP.AU Aft Pharmaceuticals Ltd

Healthcare Pharmaceuticals Australian Securities Exchange
3.62 AUD
Close of Nov 1, 2026
2.69 4.13
Market cap
AUD 380M
P/E
30.2x
P/B
4.31x
ROE
13.4%
Dividend yield
0.37%
Fundamental score
2.7/5

Ratios use the latest price and the fiscal year ending Mar 2026.

Is AFP.AU undervalued?

Graham number
Price3.62
Graham value1.51
Premium140.5%

AFP.AU trades 140.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aft Pharmaceuticals Ltd fundamental analysis

13 of 22 checks passed

ROE 1/2

Moderate return on equity (13.4%), between 10% and 20%.

ROA 1/1

Return on assets (6.8%) is above the industry median (-8.9%).

Profit Consistency 2/2

Profitable for 7 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (24.0%) is above the 5-year average (13.8% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (24.0%) is below the industry median (42.8%).

Revenue Growth 2/2

Revenue grew 17.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (49.1%), up to 100%.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 10.0x against interest expense, well covered.

PE vs Market 0/1

PE (30.2x) is above the market median (15.0x).

PE vs Industry 0/1

PE (30.2x) is above the industry median (21.9x).

PBV 0/1

Price to book (4.3x) is above the industry median (2.0x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 130.2, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 2.19, above 1.

Dividend Yield 0/2

Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 12.8%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Aft Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aft Pharmaceuticals Ltd

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a …

Full company profile